Recruiting

Spinal Simplicity

Sponsor:

Spinal Simplicity LLC

Code:

NCT06355791

Conditions

Degenerative Conditions of the Lumbar Spine

Lumbar Spinal Stenosis

Spondylolisthesis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Minuteman G5 Device

Study Details

Brief summary:

This is a prospective, multi-center open-label single arm post-market study where the purpose is to evaluate the effectiveness and safety of the market approved Spinal Simplicity Minuteman G5 MIS Fusion Plate and bone graft material in patients with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication. The indication for the device under study is degenerative conditions of the lumbar spine resulting in back pain with lower extremity symptoms and neurogenic claudication.

Conditions

Degenerative Conditions of the Lumbar Spine

Lumbar Spinal Stenosis

Spondylolisthesis

Study ID

NCT06355791

Start date

May 29, 2024

Status verified date

Oct, 2025

Completion date

Dec, 2030

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria

A subject must MEET ALL of the following inclusion criteria:

1. Be a candidate for Spinal Simplicity Minuteman G5 Fusion Plate device per labeled indication
2. Be willing and capable of giving written consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided
3. Be willing and capable of subjective evaluation, read and understand written questionnaires, and read, understand the written informed consent
4. Be 18 years of age or older at the time of enrollment
5. Have been diagnosed with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication
6. Received at least 3 months of non-operative or conservative treatment without significant benefit in the opinion of the Investigator
7. Be willing and able to comply with study-related requirements, procedures and visits
8. Be on a stable pain medication regimen, as determined by the Investigator, for at least 30 days prior to enrolling in this study.
9. Must disclose any unresolved major issues of secondary gain (e.g., social, financial, legal), as determined by the Investigator. Including being involved in an injury claim under current litigation or has a pending or approved worker's compensation claim. Subjects will not be excluded due to secondary gain, but it should be disclosed at Enrollment.

Exclusion Criteria

A subject must NOT MEET ANY of the following exclusion criteria:

1. Had previous spinal surgery at the level of intervention (e.g. lumbar fusion, discectomy, Laminectomy) MILD procedure is not considered an exclusion.
2. Patient physically unable to perform the Gait and/or Balance tests.
3. Current systemic infection or local infection increasing the risk of surgery
4. History of medications decreasing bone quality or soft tissue healing in the opinion of the Investigator
5. Grade II-V spondylolisthesis
6. Significant scoliosis with Cobb angle >10 degrees
7. Unremitting back pain in a spinal flexion position
8. Active systemic disease that may affect the welfare of the subject in the opinion of the Investigator
9. Be concurrently participating in another clinical drug and/or device study that may alter or confound the results of the assessment (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) as determined by the investigator.
10. Vertebral osteoporosis or history of vertebral fracture
11. Be pregnant/ lactating or plan to become pregnant from study enrollment through 3 months post-operatively. (determined by urine testing unless female subject is surgical sterile or post-menopausal). If female, sexually active and childbearing age, subject must be willing to use a reliable form of birth control through the 3-month visit.
12. Malformation or dysplasia of spinous process
13. Severe osteoporosis with T score <-2.5 SD

Study Design

Enrollment

150 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Surgical Group

patient treated with Minuteman G5 interspinous fusion device 510k cleared for degenerative conditions of the lumbar spine

Interventions

Minuteman G5 Device

The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy

Primary outcome measure

  • Pain (Overall, Back and Leg) using NRS/numeric rating scale [ Time Frame: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years. ]
  • Oswestry Disability Index (ODI) [ Time Frame: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years. ]
  • PROMIS 29 2.0 [ Time Frame: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years. ]
  • Assessment of Motion using BioMech Lab testing equipment [ Time Frame: Baseline and 1-, 3- and 12-months post implantation. ]
  • Zurich Classification Questionnaire (ZCQ) [ Time Frame: Baseline and 1-, 3- 6- and 12-months post implantation; annually out to five years. ]

Central Contacts and Locations

Locations

Vista Clinical Research

Recruiting

Newnan, Georgia, United States, 30265

Principal Investigator:

Sandeep Vaid, MD

Comprehensive Pain & Spine Specialists

Recruiting

Indianapolis, Indiana, United States, 46250

Principal Investigator:

Andrew Trobridge, MD

Nura Precision Pain Management

Recruiting

Edina, Minnesota, United States, 55435

Principal Investigator:

R. Scott Stayner, MD

Pacific Sports & Spine

Recruiting

Eugene, Oregon, United States, 97404

Principal Investigator:

Gregory Moore, MD

Spine & Nerve Center of the Virginias

Recruiting

Charleston, West Virginia, United States, 25301

Principal Investigator:

Timothy Deer, MD

More Information

Sponsor

Spinal Simplicity LLC

Last update posted

Oct 3, 2025

Last verified

Oct, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Spinal Simplicity LLC on 2025-10-03.